MedTech Dive March 29, 2024
The chairman of J&J subsidiary DePuy Synthes talked about how surgical robots and other technologies have contributed to procedures moving to outpatient facilities.
Johnson & Johnson’s orthopedics unit is undergoing several changes as it looks to enter high-growth markets. Last year, J&J announced the unit would exit less profitable markets and product lines. The company is also looking to expand its surgical robot, Velys, which received FDA clearance in 2021 for total knee procedures and a CE mark in 2023.
Last year, the orthopedics unit reported sales of $8.94 billion, roughly a 5% increase year over year.
Aldo Denti, chairman of DePuy Synthes, spoke with MedTech Dive about the company’s strategic priorities, and the role of technology as more...
Today's Sponsors
Today's Sponsor